| ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder M Kato, T Fukuda, A Serretti, M Wakeno, G Okugawa, Y Ikenaga, Y Hosoi, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (2), 398-404, 2008 | 181 | 2008 |
| ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder M Kato, T Fukuda, A Serretti, M Wakeno, G Okugawa, Y Ikenaga, Y Hosoi, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (2), 398-404, 2008 | 181 | 2008 |
| Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese … M Kato, T Fukuda, M Wakeno, K Fukuda, G Okugawa, Y Ikenaga, ... Neuropsychobiology 53 (4), 186-195, 2006 | 177 | 2006 |
| Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder M Kato, T Fukuda, M Wakeno, G Okugawa, Y Takekita, S Watanabe, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 150 …, 2009 | 106 | 2009 |
| Differences in quantitative EEG between frontotemporal dementia and Alzheimer’s disease as revealed by LORETA K Nishida, M Yoshimura, T Isotani, T Yoshida, Y Kitaura, A Saito, H Mii, ... Clinical Neurophysiology 122 (9), 1718-1725, 2011 | 94 | 2011 |
| The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran M Wakeno, M Kato, G Okugawa, T Fukuda, Y Hosoi, Y Takekita, ... Journal of clinical psychopharmacology 28 (5), 518-524, 2008 | 44 | 2008 |
| Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials Y Takekita, T Suwa, N Sunada, H Kawashima, C Fabbri, M Kato, A Tajika, ... European archives of psychiatry and clinical neuroscience 266, 703-717, 2016 | 37 | 2016 |
| Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients M Kato, M Wakeno, G Okugawa, T Fukuda, Y Takekita, Y Hosoi, J Azuma, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (4), 1041-1044, 2008 | 35 | 2008 |
| Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis K Matsui, T Tokumasu, Y Takekita, K Inada, T Kanazawa, T Kishimoto, ... Schizophrenia research 209, 50-57, 2019 | 34 | 2019 |
| The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled … Y Koshikawa, Y Takekita, M Kato, S Sakai, A Onohara, N Sunada, ... Neuropsychobiology 73 (1), 35-42, 2016 | 34 | 2016 |
| Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects M Kato, G Okugawa, M Wakeno, Y Takekita, S Nonen, S Tetsuo, ... European neuropsychopharmacology 19 (10), 718-725, 2009 | 33 | 2009 |
| Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial Y Takekita, Y Koshikawa, C Fabbri, S Sakai, N Sunada, A Onohara, ... BMC psychiatry 16, 1-8, 2016 | 30 | 2016 |
| HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: a meta-analysis Y Takekita, C Fabbri, M Kato, Y Koshikawa, A Tajika, T Kinoshita, ... International Journal of Neuropsychopharmacology 19 (5), pyv125, 2016 | 30 | 2016 |
| HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia Y Takekita, C Fabbri, M Kato, S Nonen, S Sakai, N Sunada, Y Koshikawa, ... Journal of clinical psychopharmacology 35 (3), 220-227, 2015 | 28 | 2015 |
| Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs M Kato, A Serretti, S Nonen, Y Takekita, M Wakeno, J Azuma, T Kinoshita Translational psychiatry 5 (2), e513-e513, 2015 | 24 | 2015 |
| Therapeutic response to paroxetine in major depressive disorder predicted by DNA methylation N Takeuchi, S Nonen, M Kato, M Wakeno, Y Takekita, T Kinoshita, ... Neuropsychobiology 75 (2), 81-88, 2018 | 21 | 2018 |
| 5-HTTLPR rs25531A> G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial M Kato, S Nonen, J Azuma, A Serretti, S Tetsuo, Y Takekita, T Kinoshita Journal of clinical psychopharmacology 33 (1), 131-132, 2013 | 20 | 2013 |
| Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT M Kato, Y Takekita, Y Koshikawa, S Sakai, H Bandou, K Nishida, ... Journal of psychiatric research 89, 97-104, 2017 | 18 | 2017 |
| Polymorphism of rs3813034 in serotonin transporter gene SLC6A4 is associated with the selective serotonin and serotonin-norepinephrine reuptake inhibitor response in depressive … S Nonen, M Kato, Y Takekita, M Wakeno, S Sakai, A Serretti, T Kinoshita Journal of clinical psychopharmacology 36 (1), 27-31, 2016 | 17 | 2016 |
| A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients Y Takekita, M Kato, M Wakeno, S Sakai, A Suwa, K Nishida, G Okugawa, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 40, 110-114, 2013 | 15 | 2013 |
